# US 2011/0300139 A1 · Generation, expression and characterization of the humanized k33n monoclonal antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300139 A1
- Document ID: US20110300139A1
- Status: Published application
- Kind: A1
- Application number: 13/201,847
- Filed: 2010-03-10
- Published: 2011-12-08
- Earliest claimed: 2009-03-10
- Assignees: Gene Techno Science Co., Ltd.; Kaken Pharmaceutical Co., Ltd.
- Inventors: Shankar Kumar; J. Yun Tso; Naoya Tsurushita; Tatsuhiro Harada
- Web page: https://patentgrep.com/patent/US20110300139A1

## CPC

- C07K 16/2839: {against the integrin superfamily}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

## Claims

### Claim 1

A humanized antibody or an antigen-binding fragment thereof that immunospecifically recognizes human α9 integrin, comprising:
(i) a H-chain comprising at least one FRH derived from a VH region of a human antibody, and at least one CDRH derived from at least one of CDRHs of a non-human antibody that immunospecifically recognizes human α9 integrin; or
(ii) a L-chain comprising at least one FRL derived from a VL region of a human antibody, and at least one CDRL derived from at least one of CDRLs of a non-human antibody that immunospecifically recognizes human α9 integrin; or
(iii) both (i) and (ii) above.

### Claim 2 (depends on 1)

The humanized antibody or an antigen-binding fragment thereof of claim 1, wherein said non-human antibody is a mouse monoclonal antibody produced by a hybridoma of Depository Accession No. FERM BP-10830.

### Claim 3 (depends on 1)

The humanized antibody or an antigen-binding fragment thereof of claim 1, wherein at least one CDRH of said humanized antibody comprises an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOS:4, 5 and 6, and at least one CDRL of said humanized antibody comprises an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOS:11, 12 and 13.

### Claim 4 (depends on 2)

The humanized antibody or an antigen-binding fragment thereof of claim 2, wherein said VH region of a human antibody comprises an amino acid sequence derived from the amino acid sequence encoded by the nucleotide sequence of GenBank Accession No. DA980102 (SEQ ID NO:18), and said VL region of a human antibody comprises an amino acid sequence derived from the amino aid sequence encoded by the nucleotide sequence of GenBank Accession No. X72441 (SEQ ID NO:23).

### Claim 5

A humanized antibody or an antigen-binding fragment thereof that immunospecifically recognizes human α9 integrin, comprising a H-chain comprises the amino acid sequence of SEQ ID NO:60 and a L-chain comprises the amino acid sequence of SEQ ID NO:61.

### Claim 6

An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:60.

### Claim 7 (depends on 6)

The nucleic acid molecule of claim 6, wherein said nucleotide sequence has the nucleotide sequence of SEQ ID NO:62.

### Claim 8 (depends on 6)

The nucleic acid molecule of claim 6 further comprising a nucleotide sequence encoding a signal peptide.

### Claim 9 (depends on 8)

The nucleic acid molecule of claim 8, wherein said signal peptide comprises the amino acid sequence of SEQ ID NO:58.

### Claim 10

An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:61.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10, wherein said nucleotide sequence has the nucleotide sequence of SEQ ID NO:63.

### Claim 12 (depends on 10)

The nucleic acid molecule of claim 10 further comprising a nucleotide sequence encoding a signal peptide.

### Claim 13 (depends on 12)

The nucleic acid molecule of claim 12, wherein said signal peptide comprises the amino acid sequence of SEQ ID NO:59.

### Claim 14 (depends on 6)

A vector comprising the nucleic acid molecule of claim 6, or both, wherein said nucleic acid molecule is operably linked to one or more regulatory elements.

### Claim 15 (depends on 14)

An isolated host cell comprising the vector of claim 14.

### Claim 16 (depends on 15)

A method for preparing a humanized antibody or an antigen-binding fragment thereof, comprising culturing the host cell of claim 15 under conditions so that the humanized antibody or an antigen-binding fragment thereof is expressed, and collecting the expressed humanized antibody.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the humanized antibody or an antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 5)

A method for preventing or treating a disorder or disease associated with α9 integrin, said method comprising administering an effective amount of the humanized antibody or an antigen-binding fragment thereof of claim 5 to a subject in need thereof.

### Claim 19 (depends on 1)

A method for diagnosing a disorder or disease associated with α9 integrin in vivo, said method comprising administering an effective amount of the humanized antibody or an antigen-binding fragment thereof of claim 1 to a subject to be examined.
